



EntrezPubMedNucleotideProteinGenomeStructureOMIMPMCJournalsE

SearchPubMed▼for pseudotype retroviral particlePreviewGo

✓LimitsPreview/IndexHistoryClipboardDetails

- Search History will be lost after eight hours of inactivity.
- To combine searches use # before search number, e.g., #2 AND #6.
- Search numbers may not be continuous; all searches are represented.

Entrez
PubMed

Search	Most Recent Queries	Time	Result
#26	Search pseudotype retroviral particle Limits: Publication Date to 1999/07/09	08:41:22	<u>1</u>
#10	Search pseudotype retroviral vector Field: All Fields , Limits: Publication Date to 1999/07/09	08:40:43	<u>22</u>
#9	Search pseudotype retroviral vector	08:07:26	<u>36</u>
#8	Search pseudotype retroviral particle	08:06:54	<u>2</u>
#1	Search Kappes J	08:02:07	<u>57</u>

PubMed
Services

Clear History

Related
Resources

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Freedom of Information Act | Disclaimer

```
=> "retroviral vector"
    14579 "RETROVIRAL"
    12 "RETROVIRALS"
    14582 "RETROVIRAL"
        ("RETROVIRAL" OR "RETROVIRALS")
    130989 "VECTOR"
    77729 "VECTORS"
    177165 "VECTOR"
        ("VECTOR" OR "VECTORS")
L1      6717 "RETROVIRAL VECTOR"
        ("RETROVIRAL" (W) "VECTOR")
```

```
=> puromycin
    7386 PUROMYCIN
    21 PUROMYCINS
L2      7387 PUROMYCIN
        (PUROMYCIN OR PUROMYCINS)
```

```
=> L1 and L2
L3      44 L1 AND L2
```

```
=> marker(s) gene
    102777 MARKER
    91462 MARKERS
    163461 MARKER
        (MARKER OR MARKERS)
    846186 GENE
    319047 GENES
    895418 GENE
        (GENE OR GENES)
L4      27188 MARKER(S) GENE
```

```
=> L3 and l4
L5      15 L3 AND L4
```

L5 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1990:510408 CAPLUS

DOCUMENT NUMBER: 113:110408

TITLE: Advanced mammalian **gene** transfer: high
titer **retroviral vectors** with
multiple drug selection **markers** and a
complementary helper-free packaging cell line

AUTHOR(S): Morgenstern, Jay P.; Land, Hartmut

CORPORATE SOURCE: Imp. Cancer Res. Fund, Lincoln's Inn Fields/London,
WC2A 3PX, UK

SOURCE: Nucleic Acids Research (1990), 18(12), 3587-96

CODEN: NARHAD; ISSN: 0305-1048

DOCUMENT TYPE: Journal

LANGUAGE: English

ABSTRACT:

The development of an advanced system for transfer and expression of exogenous genes in mammalian cells based on Moloney murine leukemia virus (Mo MuLV) is reported. Extensive deletion/mutagenesis anal. to identify cis-acting signals involved in virus transmission has led to the design of a family of novel, highly efficient **retroviral vectors** and a partner helper-free packaging cell line. The pBabe **retroviral vector** constructs transmit inserted genes at high titers and express them from the Mo MuLV Long Terminal Repeat (LTR). Each of these vectors has been constructed with one of four different dominantly acting selectable markers, allowing the growth of infected mammalian cells in the presence of G418, hygromycin B, bleomycin/phleomycin or **puromycin**, resp. The high titer ecotropic helper free packaging cell line, Ω E, was designed in conjunction with the pBabe vectors to reduce the risk of generation of wild type Mo MuLV via homologous recombination events. The Ω E cell line was generated with sep. gagpol and ecotropic env expression constructs with minimal sequence overlap and decreased sequence homol. achieved by codon wobbling. Homologous env coding sequences were deleted from the pBabe vectors without diminishing recombinant vector titer. Together, the pBabe vectors and Ω E cell line should prove useful in expts. where highest frequencies of gene transfer, or concomitant expression of several different genes within a single cell are required with minimal risk of helper virus contamination.

L5 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1995:16992 CAPLUS

DOCUMENT NUMBER: 122:73268

TITLE: Versatile **retroviral vectors** for potential use in gene therapy

AUTHOR(S): Hawley, Robert G.; Lieu, Francis H. L.; Fong, Andrew Z. C.; Hawley, Teresa S.

CORPORATE SOURCE: Sunnybrook Health Sci. Cent., Univ. Toronto, Toronto, ON, M4N 3M5, Can.

SOURCE: Gene Therapy (1994), 1(2), 136-8

CODEN: GETHEC; ISSN: 0969-7128

DOCUMENT TYPE: Journal

LANGUAGE: English

ABSTRACT:

A set of **retroviral vectors** is described whose capacity for high efficiency transduction of functional genes into undifferentiated murine embryonic and hematopoietic cells makes them ideally suited for preclin. studies with murine models. Multiple unique cloning sites permit insertion of *****genes***** into the vectors such that no selectable **marker** exists or either the neomycin phosphotransferase (neo) **gene**, the hygromycin B phosphotransferase (hph) **gene** or the **puromycin** N-acetyl transferase (pac) **gene** is included as a dominantly acting selectable *****marker*****. Because the sequences in the viral gag region shown to improve the encapsidation of viral RNA have been modified to prevent viral protein synthesis and all env sequences have been removed to eliminate helper virus production by homologous recombination with packaging DNA, these vectors might prove useful in human gene therapy protocols.

L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1995:711907 CAPLUS

DOCUMENT NUMBER: 123:189590

TITLE: Construction of a **retroviral vector**
incorporating mouse VL30 retrotransposon-derived,
transcriptional regulatory sequences

AUTHOR(S): French, Neil S.; Norton, John D.

CORPORATE SOURCE: Paterson Inst. for Cancer Research, Christie Hosp
(NHS) Trust, Manchester, M20 9BX, UK

SOURCE: Analytical Biochemistry (1995), 228(2), 354-5

CODEN: ANBCA2; ISSN: 0003-2697

PUBLISHER: Academic

DOCUMENT TYPE: Journal

LANGUAGE: English

ABSTRACT:

We report here on a retrotransposon vector incorporating the LTRs of the mouse VL30NVL3 retrotransposon which are known to be highly active in a wide range of cell types including human cells. We have further engineered the vector with the extended Psi+ packaging signal derived from Moloney murine leukemia virus (MoMLV) to achieve highly efficient retrovirus encapsulation together with a multiple cloning site cassette and a **puromycin** resistance **gene** under independent control of the SV40 promoter/enhancer. Transient transfection of pNVL3puro into retroviral packaging cell lines such as PA317 and Bing (CAK8) has yielded titers of approx. 10⁴ infectious units per mL, comparable to the parental pBabepuro vector. We anticipate that this retrotransposon vector will prove to have wide utility for transduction and stable high-level expression of genes in mammalian cells both in vitro and in vivo.

An indexed library of cells containing mutations
covering the entire genome, its preparation by gene
trapping and uses

INVENTOR(S): Zambrowicz, Brian; Friedrich, Glenn A.; Bradley,
 Allan; Sands, Arthur T.
PATENT ASSIGNEE(S): Lexicon Genetics Incorporated, USA
SOURCE: U.S., 42 pp., Cont.-in-part of U.S. Ser. No. 726,867.
 CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6207371	B1	20010327	US 1997-942806	19971002
US 6136566	A	20001024	US 1996-726867	19961004
US 2002102543	A1	20020801	US 2000-728445	20001130

PRIORITY APPLN. INFO.:

US 1996-726867	A2	19961004
US 1996-728963	A2	19961011
US 1997-907598	A	19970808
US 1997-942806	A	19971002
US 1998-57328	A	19980408
US 1998-109302P	P	19981120
US 1999-276533	A	19990325
US 1999-168358P	P	19991201

ABSTRACT:

Methods and vectors (both DNA and retroviral) are provided for the construction of a library of mutated cells. The mutations are constructed using gene trapping vectors. The library will preferably contain mutations in essentially all genes present in the genome of the cells and is prepared by gene trapping on a large scale. The nature of the library and the vectors allow for methods of screening for mutations in specific genes, and for gathering nucleotide sequence data from each mutated gene to provide a database of tagged gene sequences. Such a database provides a means to access the individual mutant cell clones contained in the library. The invention includes the described library, methods of making the same, and vectors used to construct the library. Methods are also provided for accessing individual parts of the library either by sequence or by pooling and screening. The invention also provides for the generation of non-human transgenic animals which are mutant for specific genes as isolated and generated from the cells of the library. The generation of a library containing 3,000 mutations in a cell line derived from mouse embryonic stem cells is demonstrated.

REFERENCE COUNT: 110 THERE ARE 110 CITED REFERENCES AVAILABLE FOR